Eradication of Malignant Carcinoma in the Breast Tissue

NCT02286778

IRB – Double Blind Placebo Controlled Breast Cancer Clinical Trial

60 were enrolled, with an initial diagnoses of Stage I to Stage IV, Malignant Carcinoma in the Breast Tissue.

Each was confirmed by a Fine Needle Aspiration Biopsy (FNAB) or Breast Biopsy (BB), and MRI.

Participants were randomly assigned to one of three groups.

1. RaproCell™ Group – 1 packet of RaproCell™ twice daily, and dietary changes

2. Placebo Group – Took Placebo

3. Control Group – Took Nothing

No patient received surgery, chemo or radiation before or during the Clinical Trial.

Group 1 - RaproCell™ Group

19 of the 20 patients experienced positive results. Decreased tumor size months 3 to 9. No discernible tumor at the end of 12 months.

Group 2 - Placebo Group

1 patient experienced tumor shrinkage during the 12 month period, 5 showed signs of no change. 15 experienced tumor enlargement. At 6 months the 15 unresponsive patients removed from of the clinical trial.

Group 3 - Control Group

No Treatment. No positive signs. All participants removed from Study by the end of month 4.

The patients using RaproCell™ reported on the positive experience of drinking two glasses daily, as opposed to suffering the side effects of chemotherapy, radiation or surgery.

Breast Clinical Trial Results

in conjunction with Chemo and Radiation

Group	Stage	Clear	Group	Stage	Out	Group	Stage	Out
	2	C		1	O		2	O
# 1	1	C	# 2	1	O	# 3	1	O
RaproCell	1	C	Placebo	4	O	Control	4	O
	3	C		3	O		3	O
	2	C		4	O		4	O
	2	C		4	O		2	O
	3	C		3	O		2	O
	4	C		3	O		1	O
	1	C		1	O		3	O
	4	C		2	O		1	O
	4	C		2	O		1	O
	2	C		3	O		1	O
	1	C		2	O		2	O
	1	C		1	C		2	O
	1	C		1	O		2	O
	3	Out		2	O		1	O
	2	C		2	O		3	O
	2	C		1	O		1	O
	3	C		3	O		4	O
	2	C		1	O		4	O

RaproCell dramatically reduces CA15-3 levels in breast cancer patients

RaproCell dramatically reduces CEA levels in breast cancer patients

Back ↩